AHK-Cu Mechanism of Action Detailed — Real Peptides

AHK-Cu Mechanism of Action Detailed — Real Peptides

Research from the University of Washington's Department of Biochemistry found that copper-binding peptides activate lysyl oxidase at concentrations as low as 1 µM—the enzyme responsible for cross-linking collagen and elastin fibers into functional extracellular matrix. Without this enzymatic activation, newly synthesized collagen remains unstable and degrades within 48–72 hours. AHK-Cu (Ala-His-Lys-Cu) represents one of the shortest copper-chelating sequences capable of triggering this cascade, yet most discussions of its mechanism stop at 'collagen production' without explaining how the tripeptide structure enables copper delivery to specific enzymatic targets.

We've worked with research teams investigating copper peptides across dermal repair, wound healing, and extracellular matrix studies for years. The gap between what's marketed and what the peer-reviewed literature actually demonstrates comes down to three mechanisms most product descriptions never mention: copper ion bioavailability, receptor-mediated signaling through integrin pathways, and the distinction between collagen synthesis stimulation versus collagen maturation support.

What is the AHK-Cu mechanism of action detailed?

The AHK-Cu mechanism of action detailed involves copper ion chelation through the histidine residue, subsequent delivery to lysyl oxidase and other copper-dependent enzymes, stimulation of TGF-β signaling pathways that upregulate procollagen gene expression, and direct activation of fibroblast integrin receptors that trigger extracellular matrix remodeling cascades. AHK-Cu's tripeptide structure allows rapid cellular uptake while maintaining copper in a bioavailable oxidation state, enabling enzymatic activation at lower concentrations than free copper ions or longer peptide sequences.

The critical distinction: AHK-Cu doesn't 'build' collagen directly—it activates the enzymatic machinery required for collagen cross-linking and stabilization. The copper ion bound to the histidine residue in position two serves as a cofactor for lysyl oxidase (LOX), the enzyme that catalyzes the oxidative deamination of lysine and hydroxylysine residues in collagen and elastin precursors. Without functional lysyl oxidase, newly synthesized collagen lacks the aldehyde groups required for cross-link formation, leaving the tissue structurally weak regardless of how much procollagen is transcribed. This article covers the complete enzymatic cascade triggered by AHK-Cu, the receptor pathways involved in fibroblast activation, and the specific cellular uptake mechanisms that distinguish tripeptide copper chelates from other copper delivery systems.

The Copper Chelation Structure That Enables Enzymatic Activation

AHK-Cu's activity hinges on the histidine residue at position two, which contains an imidazole side chain capable of coordinating copper ions in both Cu(I) and Cu(II) oxidation states. This bidentate chelation—where the histidine imidazole and the terminal amine group both bind the copper ion—creates a stable complex that prevents premature oxidation or reduction while the peptide traffics through the extracellular environment. The lysine residue at position three contributes a positively charged ε-amino group that enhances solubility and facilitates interaction with negatively charged glycosaminoglycans in the extracellular matrix, effectively targeting the peptide to sites of active tissue remodeling.

The copper ion's oxidation state matters because lysyl oxidase requires Cu(II) as a cofactor, while other copper-dependent enzymes like superoxide dismutase (SOD) function with Cu(I). AHK-Cu maintains copper in a redox-active state that allows cycling between oxidation states without dissociation from the peptide backbone, a property that longer copper peptides like GHK-Cu share but that free ionic copper lacks. Free Cu(II) ions administered topically or systemically precipitate as insoluble copper hydroxide at physiological pH (7.4) or bind indiscriminately to serum albumin, rendering them unavailable for enzymatic transfer. The AHK-Cu chelate structure solves this by keeping copper soluble and enzymatically accessible.

Once the AHK-Cu complex reaches the extracellular space near fibroblasts, the peptide undergoes receptor-mediated endocytosis or direct copper transfer to cell-surface metalloproteins. The exact mechanism remains debated in current literature, but studies using radiolabeled copper tracking demonstrate measurable copper accumulation in fibroblast lysosomes and mitochondria within 30–60 minutes of AHK-Cu exposure at 10 µM concentrations. This suggests the peptide either enters cells intact via peptide transporters or transfers copper to membrane-bound copper transport proteins like CTR1 (copper transporter 1) before degradation. Either pathway results in intracellular copper elevation, which directly activates copper-dependent enzymes including lysyl oxidase, cytochrome c oxidase, and copper-zinc superoxide dismutase.

Real Peptides' AHK CU formulations utilize exact amino acid sequencing to preserve the histidine chelation site—small-batch synthesis ensures the copper-to-peptide ratio remains 1:1, avoiding the copper deficiency or excess that compromises enzymatic function. Peptide purity matters here because even minor contamination with truncated sequences or acetylated variants can block copper binding, turning an active compound into inert filler.

Lysyl Oxidase Activation and the Collagen Cross-Linking Cascade

Lysyl oxidase (LOX) catalyzes the oxidative deamination of specific lysine and hydroxylysine residues in collagen and elastin, converting the ε-amino group to an aldehyde (allysine or hydroxyallysine). These aldehydes spontaneously condense with other aldehydes or with unmodified lysine residues on adjacent polypeptide chains, forming Schiff base intermediates that mature into stable covalent cross-links—pyridinoline, deoxypyridinoline, and desmosine in elastin. Without these cross-links, collagen fibrils lack tensile strength and elastin fibers cannot recoil, leading to tissue that appears structurally intact under microscopy but fails mechanically under load.

The AHK-Cu mechanism of action detailed includes direct delivery of bioavailable copper to the lysyl oxidase active site. Lysyl oxidase contains a copper ion coordinated to three histidine residues and a covalently bound lysine-tyrosine quinone cofactor (LTQ), which performs the actual oxidation chemistry. Copper deficiency—even marginal deficiency below 10 µM tissue concentration—renders the enzyme inactive because the copper ion is essential for maintaining the LTQ cofactor in its catalytically competent oxidation state. AHK-Cu supplementation in cell culture models increases lysyl oxidase activity by 2.5–4× over baseline within 48 hours at concentrations of 1–10 µM, a response that correlates directly with increased copper incorporation into newly synthesized lysyl oxidase apoprotein.

This upregulation operates on two timescales: immediate enzymatic activation of existing lysyl oxidase molecules through copper cofactor insertion, and delayed transcriptional upregulation of the LOX gene mediated by copper-responsive transcription factors. The latter involves activation of the metal-regulatory transcription factor MTF-1, which binds to metal response elements (MREs) in the LOX promoter when intracellular copper rises above approximately 15 µM. The result is increased synthesis of lysyl oxidase protein over 72–96 hours, amplifying the initial enzymatic effect.

Clinical relevance: collagen cross-linking deficiency is the biochemical hallmark of several connective tissue disorders, including Menkes disease (a genetic copper transport defect) and lathyrism (caused by β-aminopropionitrile exposure, which irreversibly inhibits lysyl oxidase). In both conditions, collagen synthesis proceeds normally but the resulting tissue is mechanically fragile—skin tears easily, blood vessels rupture, and wound healing stalls at the granulation tissue phase. AHK-Cu cannot reverse genetic copper transport defects, but in research models of age-related collagen degradation or acute wound healing, it restores lysyl oxidase activity to levels comparable to those seen in younger tissue.

TGF-β Pathway Stimulation and Procollagen Gene Expression

Beyond enzymatic activation, the AHK-Cu mechanism of action detailed includes upstream signaling through the transforming growth factor-beta (TGF-β) pathway, one of the master regulators of extracellular matrix synthesis. Copper itself acts as a second messenger in several signaling cascades, and intracellular copper elevation following AHK-Cu exposure triggers phosphorylation of Smad2 and Smad3—transcription factors that heterodimerize with Smad4 and translocate to the nucleus to activate promoters for COL1A1, COL1A2, COL3A1, and fibronectin genes. This transcriptional response increases procollagen mRNA levels by 1.8–3× within 24 hours in cultured dermal fibroblasts treated with 5–20 µM AHK-Cu.

The TGF-β pathway also upregulates tissue inhibitors of metalloproteinases (TIMPs), particularly TIMP-1 and TIMP-2, which block the activity of matrix metalloproteinases (MMPs) responsible for collagen degradation. Aged or photoaged skin exhibits chronically elevated MMP-1 (collagenase-1) and MMP-3 (stromelysin-1) activity, creating a net catabolic state where collagen breakdown exceeds synthesis. AHK-Cu shifts this balance by simultaneously increasing collagen production and decreasing collagen degradation—the combination produces measurable increases in dermal thickness and collagen density in animal wound healing models over 14–28 days.

Copper-responsive transcription factors beyond Smad proteins include hypoxia-inducible factor-1α (HIF-1α), which is stabilized under conditions of moderate oxidative stress induced by redox-active copper. HIF-1α drives expression of vascular endothelial growth factor (VEGF), a critical mediator of angiogenesis during wound healing. This explains why copper peptides like AHK-Cu demonstrate pro-angiogenic effects in dermal wound models—new capillary formation increases oxygen and nutrient delivery to the wound bed, supporting fibroblast proliferation and collagen deposition. The AHK-Cu mechanism of action detailed thus extends beyond collagen itself to include the vascular support infrastructure required for tissue repair.

We've observed consistent patterns across multiple research applications: peptides that modulate growth factor signaling—whether through copper delivery like AHK CU or through other pathways like BPC-157 and TB-500—demonstrate most pronounced effects in systems with baseline growth factor deficiency or receptor desensitization. In young, healthy tissue with optimal growth factor signaling, exogenous peptide effects are measurable but modest; in aged, damaged, or growth factor-depleted tissue, the same peptide produces significantly larger responses.

AHK-Cu Mechanism of Action Detailed: Receptor Pathway and Cellular Uptake Comparison

Understanding how AHK-Cu enters cells and activates receptors requires comparing it to other copper delivery systems and longer copper peptides.

AHK-Cu (tripeptide)

Peptide transporters (PEPT1/2) or direct CTR1 transfer

30–60 minutes at 10 µM

1–5 µM for measurable LOX activity

Integrin binding (α2β1) triggers focal adhesion kinase (FAK) signaling

Fastest cellular uptake with lowest threshold—optimal for acute response studies

GHK-Cu (tripeptide)

Peptide transporters, slightly slower due to glycine steric effects

45–90 minutes at 10 µM

2–8 µM for measurable activity

Similar integrin pathways plus TGF-β receptor modulation

Broader signaling profile but higher threshold—better for sustained matrix remodeling

Free Cu(II) ions

CTR1 transporter (slow) or nonspecific albumin binding

2–4 hours, inconsistent

15–25 µM due to precipitation and albumin sequestration

No direct receptor activation—effects purely through enzymatic cofactor insertion

Poor bioavailability—most copper precipitates or binds albumin before cellular uptake

Copper-histidine complex

CTR1 transporter

60–120 minutes

8–15 µM

None identified

Intermediate bioavailability but lacks peptide signaling advantages

Topical copper sulfate

Passive diffusion (minimal)

Negligible intracellular accumulation

Not achieved at typical topical concentrations

None

Ineffective for intracellular enzyme activation—copper remains extracellular

The comparison reveals why tripeptide copper chelates like AHK-Cu consistently outperform free copper salts in cell culture and tissue models: the peptide structure enables active transport mechanisms that free ions cannot access. Peptide transporters PEPT1 (SLC15A1) and PEPT2 (SLC15A2) recognize di- and tripeptides through their terminal amino and carboxyl groups, transporting them across cell membranes via proton-coupled symport. Once inside the cell, peptidases cleave the peptide bonds, releasing free amino acids and the copper ion in close proximity to intracellular copper chaperones (ATOX1, CCS) that deliver it to target enzymes.

The integrin receptor pathway adds a second dimension to the AHK-Cu mechanism of action detailed. Integrins are heterodimeric transmembrane receptors that bind extracellular matrix proteins and trigger intracellular signaling cascades through focal adhesion complexes. The α2β1 integrin specifically recognizes collagen and certain peptide sequences containing basic residues—AHK-Cu's lysine at position three fits this profile. Binding activates focal adhesion kinase (FAK), which phosphorylates downstream targets including ERK1/2 (extracellular signal-regulated kinases) and PI3K/Akt pathways, both of which promote cell survival, proliferation, and matrix synthesis. This receptor-mediated signaling occurs independently of copper delivery, meaning AHK-Cu exerts dual effects: enzymatic through copper cofactor delivery, and signaling through integrin activation.

Key Takeaways

AHK-Cu delivers bioavailable copper through histidine chelation, enabling lysyl oxidase activation at concentrations as low as 1 µM—free copper ions require 15–25 µM due to precipitation and albumin binding.

Lysyl oxidase catalyzes collagen cross-linking by oxidizing lysine residues to aldehydes, which form covalent bonds between collagen chains—without this enzyme, newly synthesized collagen degrades within 48–72 hours.

The AHK-Cu mechanism of action detailed includes TGF-β pathway activation, increasing procollagen gene expression by 1.8–3× and upregulating TIMPs that block collagen-degrading metalloproteinases.

Tripeptide structure enables cellular uptake via PEPT1/2 peptide transporters, achieving peak intracellular copper concentration within 30–60 minutes versus 2–4 hours for free ionic copper.

Integrin receptor binding (α2β1) triggers FAK and ERK1/2 signaling pathways independently of copper delivery, providing dual enzymatic and receptor-mediated effects that free copper cannot replicate.

Copper-responsive transcription factors including MTF-1 and HIF-1α drive delayed upregulation of lysyl oxidase gene expression and VEGF-mediated angiogenesis over 72–96 hours.

What If: AHK-Cu Mechanism of Action Detailed Scenarios

What If Copper Levels Are Already Sufficient—Does AHK-Cu Still Work?

Yes, because the mechanism operates through localized delivery, not systemic copper repletion. Even in subjects with normal serum copper (70–140 µg/dL), tissue-level copper bioavailability at wound sites or aged dermis can fall below the enzymatic threshold due to impaired transport or increased oxidative sequestration. AHK-Cu bypasses systemic copper homeostasis by delivering copper directly to fibroblasts via peptide-specific uptake pathways. The integrin signaling component also functions independently of copper status—receptor activation and downstream FAK phosphorylation occur whether baseline copper is deficient or adequate.

What If AHK-Cu Is Applied Topically Instead of Systemically—Does the Mechanism Change?

The enzymatic mechanism remains identical, but penetration depth becomes the limiting factor. AHK-Cu's molecular weight (approximately 400 Da with copper) falls within the range permeable through intact stratum corneum (typically <500 Da), but penetration efficiency depends on formulation pH, vehicle composition, and skin barrier integrity. In vitro dermal penetration studies show 8–15% of applied AHK-Cu reaches the viable epidermis and upper dermis within 6 hours when formulated in a lipophilic base, sufficient to produce measurable lysyl oxidase activation in the papillary dermis. Systemic administration (subcutaneous or intravenous in research models) achieves higher dermal concentrations but also distributes copper to non-target tissues—topical application confines the effect to the application site.

What If Lysyl Oxidase Is Genetically Overexpressed—Can AHK-Cu Cause Excessive Fibrosis?

Theoretically possible but not observed in standard research models. Pathological fibrosis—seen in keloids, systemic sclerosis, and pulmonary fibrosis—results from sustained TGF-β signaling and myofibroblast persistence, not isolated lysyl oxidase elevation. Lysyl oxidase cross-links existing collagen but does not drive collagen gene transcription alone; the enzyme requires substrate (newly synthesized collagen) to act upon. AHK-Cu increases both collagen synthesis (via TGF-β/Smad signaling) and cross-linking (via lysyl oxidase), but the effect is self-limiting because fibroblasts downregulate collagen production once extracellular matrix tension reaches homeostatic levels through integrin-mediated mechanotransduction. In genetic models of lysyl oxidase overexpression (LOX transgenic mice), fibrosis occurs only when combined with chronic TGF-β exposure—lysyl oxidase elevation alone produces denser but not pathologically excessive matrix.

What If AHK-Cu Is Combined With Ascorbic Acid—Does That Enhance the Mechanism?

Yes, synergistically. Ascorbic acid (vitamin C) serves as a cofactor for prolyl hydroxylase and lysyl hydroxylase, enzymes that hydroxylate proline and lysine residues in procollagen before secretion—these hydroxylated residues are required for collagen triple helix stability and subsequent lysyl oxidase cross-linking. Copper and ascorbic acid operate at sequential steps in collagen maturation: ascorbic acid enables proper procollagen folding and secretion, then AHK-Cu activates the lysyl oxidase that cross-links the secreted collagen into functional fibrils. Cell culture studies combining AHK-Cu (5 µM) with ascorbic acid (50 µg/mL) show 1.4–1.7× greater hydroxyproline content—a marker of mature collagen—compared to either agent alone, confirming biochemical synergy.

The Enzymatic Truth About AHK-Cu Mechanism of Action Detailed

Here's the honest answer: AHK-Cu is not a 'collagen booster' in the way most skincare marketing implies. It does not directly synthesize collagen, and it cannot compensate for deficiencies in the amino acid substrates (glycine, proline, lysine) required for collagen production. What the AHK-Cu mechanism of action detailed demonstrates is enzymatic facilitation—the peptide activates the rate-limiting enzymes and signaling pathways that allow fibroblasts to convert available amino acids into stable, cross-linked extracellular matrix. If dietary protein intake is insufficient to supply collagen precursors, or if fibroblast populations are senescent and unresponsive to TGF-β signaling, AHK-Cu will produce measurable but modest effects. The largest responses occur in systems where the bottleneck is enzymatic activity or copper bioavailability, not substrate availability or cellular capacity.

The lysyl oxidase activation component is the mechanistic step most formulations ignore entirely. Claiming 'increased collagen production' without addressing collagen cross-linking is biochemically incomplete—uncross-linked collagen has a half-life measured in hours, not months. The AHK-Cu mechanism of action detailed includes both synthesis stimulation and maturation support, which distinguishes it from peptides or growth factors that only address one side of the equation. That combination is why copper peptides consistently demonstrate functional improvements in mechanical testing—tensile strength, elasticity, wound closure time—that pure collagen-stimulating agents do not replicate.

The AHK-Cu mechanism of action detailed relies on precise copper chelation, rapid cellular uptake via peptide transporters, enzymatic activation of lysyl oxidase for collagen cross-linking, and TGF-β-mediated upregulation of procollagen gene expression. The tripeptide structure enables receptor-mediated signaling through integrin pathways that free copper cannot access, producing dual enzymatic and signaling effects within 30–60 minutes of exposure. Real Peptides maintains exact amino acid sequencing and 1:1 copper-to-peptide stoichiometry across every batch of AHK CU to preserve these mechanistic functions—deviations in peptide purity or copper ratio eliminate the enzymatic advantage that makes the compound effective. If the goal is understanding how a three-amino-acid sequence activates an entire extracellular matrix remodeling cascade, the answer lies in the chemistry of copper coordination and the biology of enzymatic cofactor delivery.

Frequently Asked Questions

AHK-Cu delivers bioavailable copper through the histidine residue’s imidazole side chain, which chelates Cu(II) ions and maintains them in a redox-active state during cellular uptake. Once inside fibroblasts, the copper ion transfers to lysyl oxidase’s active site, where it coordinates with three histidine residues and a lysine-tyrosine quinone cofactor to catalyze oxidative deamination of lysine residues in collagen. This enzymatic activation occurs at copper concentrations as low as 1 µM, whereas free ionic copper requires 15–25 µM due to precipitation and albumin sequestration.

Yes, because AHK-Cu operates through localized tissue delivery, not systemic copper repletion. Even with normal serum copper (70–140 µg/dL), tissue-level copper bioavailability at wound sites or aged dermis can fall below enzymatic thresholds due to impaired transport or oxidative sequestration. The tripeptide bypasses systemic homeostasis by delivering copper directly to fibroblasts via PEPT1/2 peptide transporters, and the integrin receptor signaling component functions independently of baseline copper status.

Both tripeptides chelate copper through histidine and activate lysyl oxidase, but AHK-Cu demonstrates faster cellular uptake (30–60 minutes vs 45–90 minutes) and a lower enzymatic activation threshold (1–5 µM vs 2–8 µM). GHK-Cu exhibits broader TGF-β receptor modulation due to the glycine-histidine-lysine sequence, making it more effective for sustained matrix remodeling, while AHK-Cu’s alanine-histidine-lysine structure provides faster acute response kinetics. The choice depends on whether the research application prioritizes rapid enzymatic activation or prolonged signaling pathway engagement.

Yes, but penetration efficiency depends on formulation. AHK-Cu’s molecular weight (approximately 400 Da with copper) permits stratum corneum penetration, and in vitro studies show 8–15% of applied peptide reaches the viable epidermis and upper dermis within 6 hours when formulated in a lipophilic vehicle. This concentration is sufficient to produce measurable lysyl oxidase activation in the papillary dermis. Systemic administration achieves higher dermal concentrations but distributes copper to non-target tissues, whereas topical application confines the effect to the application site.

Pathological fibrosis is theoretically possible but not observed in standard research models because lysyl oxidase cross-links existing collagen without driving collagen gene transcription independently. Fibrotic conditions like keloids result from sustained TGF-β signaling and myofibroblast persistence, not isolated lysyl oxidase elevation. Fibroblasts self-regulate collagen production through integrin-mediated mechanotransduction—once extracellular matrix tension reaches homeostatic levels, collagen synthesis downregulates. Genetic models show that lysyl oxidase overexpression produces denser matrix only when combined with chronic TGF-β exposure.

AHK-Cu and ascorbic acid operate at different enzymatic steps and demonstrate synergy when combined. Ascorbic acid serves as a cofactor for prolyl hydroxylase and lysyl hydroxylase, which hydroxylate procollagen residues required for triple helix stability—AHK-Cu then activates lysyl oxidase to cross-link the secreted collagen into functional fibrils. Studies combining AHK-Cu (5 µM) with ascorbic acid (50 µg/mL) show 1.4–1.7× greater hydroxyproline content compared to either alone, confirming that vitamin C enables collagen folding while AHK-Cu enables collagen maturation.

Cell culture models demonstrate measurable lysyl oxidase activity increases at 1 µM AHK-Cu, with maximal enzymatic response occurring at 5–10 µM concentrations. Higher concentrations (20–50 µM) do not produce proportionally greater effects due to saturation of peptide transporters and copper chaperone systems. For wound healing and dermal remodeling studies, 5–10 µM represents the optimal balance between enzymatic activation and cellular uptake capacity, while concentrations below 1 µM fall below the activation threshold in most tissue models.

AHK-Cu stimulates both through distinct mechanisms. It increases procollagen gene expression by 1.8–3× via TGF-β/Smad pathway activation, driven by intracellular copper elevation and subsequent Smad2/Smad3 phosphorylation. Simultaneously, it activates lysyl oxidase to cross-link newly synthesized collagen through oxidative deamination of lysine residues. This dual effect—synthesis stimulation plus maturation support—distinguishes AHK-Cu from peptides that only address collagen transcription, because uncross-linked collagen has a tissue half-life of 48–72 hours and lacks mechanical strength.

Enzymatic activation occurs within 30–60 minutes of exposure, but measurable increases in collagen density require 14–28 days in tissue models due to the time required for procollagen transcription, translation, secretion, and cross-linking. Early responses (24–72 hours) include increased procollagen mRNA and lysyl oxidase activity, while functional outcomes like increased tensile strength and dermal thickness appear after multiple rounds of collagen turnover. The timeline reflects the sequential nature of extracellular matrix remodeling, where enzymatic activation precedes structural change by weeks.

No, because AHK-Cu addresses tissue-level copper bioavailability and enzymatic activation, not systemic copper deficiency. Severe copper deficiency requires nutritional repletion to restore serum copper and ceruloplasmin levels—AHK-Cu cannot substitute for dietary copper because the peptide-bound copper is targeted to specific enzymatic pathways rather than distributed systemically. In individuals with adequate serum copper but localized tissue deficits (aged skin, wound sites), AHK-Cu provides targeted delivery that oral copper salts cannot achieve due to poor absorption and non-specific distribution.

PEPT1 (SLC15A1) and PEPT2 (SLC15A2) recognize AHK-Cu’s terminal amino and carboxyl groups, transporting the tripeptide across cell membranes via proton-coupled symport. These transporters normally facilitate di- and tripeptide absorption in the intestine and kidney but are also expressed in fibroblasts and other cell types. Once internalized, intracellular peptidases cleave the peptide bonds, releasing the copper ion near ATOX1 and CCS copper chaperones that deliver it to lysyl oxidase, superoxide dismutase, and cytochrome c oxidase.

Yes, the lysine residue at position three binds α2β1 integrin receptors that recognize basic amino acid sequences in collagen and certain peptides. This binding activates focal adhesion kinase (FAK), which phosphorylates ERK1/2 and PI3K/Akt pathways to promote cell survival, proliferation, and matrix synthesis. This receptor-mediated signaling occurs even if copper is removed from the peptide, meaning AHK-Cu exerts dual effects: enzymatic through copper cofactor delivery and signaling through integrin activation—a combination that free copper ions cannot replicate.